ADHD Medications: Complete Guide for Parents and Adults

Understanding ADHD and Its Treatment

Attention-Deficit/Hyperactivity Disorder (ADHD) affects approximately 8-10% of children and 4-5% of adults worldwide. It is characterized by inattention, hyperactivity, and impulsivity that impair functioning in academic, occupational, and social domains. ADHD is among the most well-studied psychiatric conditions — and its medications are among the most effective in all of psychiatry, with response rates exceeding 70-80%.

Despite decades of research confirming their safety and efficacy, ADHD medications remain surrounded by misconceptions. This guide provides evidence-based information to help patients and families make informed treatment decisions.

---

How ADHD Medications Work

The core neurobiological deficit in ADHD involves dysregulation of catecholamine neurotransmission — specifically dopamine and norepinephrine — in prefrontal cortical circuits that regulate attention, working memory, impulse control, and executive function.

Stimulants increase dopamine and norepinephrine availability by:

• Blocking reuptake transporters (methylphenidate class)
• Promoting neurotransmitter release (amphetamine class)
• Both mechanisms (amphetamine class)

Non-stimulants target norepinephrine selectively (atomoxetine, viloxazine) or modulate norepinephrine receptors (guanfacine, clonidine).

The paradoxical "calming" effect of stimulants in ADHD occurs because they optimize prefrontal cortex function — improving the top-down regulation of attention and impulse control.

---

Stimulant Medications: First-Line Treatment

Methylphenidate Class

Immediate-Release (IR):

• Ritalin, Methylin — 3-5 hour duration; dosing flexibility; lower abuse potential than amphetamines per DEA (though both are Schedule II)
• Starting dose: 5 mg bid-tid in children; titrate by 5-10 mg weekly
• Useful for targeted coverage (school day only)

Extended-Release (ER/XR/LA):

• Concerta (OROS-MPH) — 8-12 hour coverage; unique osmotic pump delivery; cannot be crushed
• Ritalin LA, Metadate CD — bead systems with 30/70 split (immediate/delayed); capsules can be opened
• Quillivant XR — liquid formulation; useful for children with swallowing difficulties
• Jornay PM — taken in the evening (6-9 pm), releases in the morning; targets morning symptom burden and reduces insomnia vs morning dosing

Transdermal:

• Daytrana patch — 9-hour patch for children 6+; applied to hip; flexible dosing by patch size and wear time; useful for patients who cannot swallow pills

Amphetamine Class

Mixed Amphetamine Salts:

• Adderall (IR) — 4-6 hour duration; 75% dextroamphetamine, 25% levoamphetamine
• Adderall XR — 8-10 hour duration; bead system (50/50 immediate/delayed release)

Dextroamphetamine:

• Dexedrine, ProCentra — pure d-amphetamine; slightly different profile than mixed salts

Lisdexamfetamine (Vyvanse):

• Prodrug — inactive until converted to d-amphetamine by intestinal enzymes
• Smoother onset; lower abuse potential (cannot be intranasally abused)
• Approved for both ADHD and binge eating disorder
• Once-daily dosing; 10-14 hour duration

Amphetamine liquid/patch:

• Adzenys XR-ODT, Dyanavel XR — liquid and orally-disintegrating amphetamine formulations

---

Non-Stimulant Medications

Atomoxetine (Strattera)

• Class: Selective norepinephrine reuptake inhibitor (SNRI)
• Onset: 2-6 weeks for full effect (unlike stimulants which work same day)
• Duration: 24-hour coverage; once or twice daily
• Advantages: No abuse potential; not a controlled substance; treats comorbid anxiety; useful when stimulants cause unacceptable side effects
• Disadvantages: Slower onset; less effective than stimulants on average; rare but serious hepatotoxicity; black box warning for suicidality in children (like all SNRIs)
• Dose: Start 0.5 mg/kg/day; target 1.2-1.4 mg/kg/day (children); 80-100 mg/day (adults)

Viloxazine (Qelbree)

• Approved 2021 for ages 6+ (2022 for adults)
• Norepinephrine reuptake inhibitor with additional serotonin effects
• QTc prolongation risk — ECG monitoring in at-risk patients
• Once daily; 100-400 mg/day

Alpha-2 Agonists (Adjunctive or Monotherapy)

Guanfacine (Intuniv ER) and Clonidine (Kapvay ER):

• Originally antihypertensives; modulate prefrontal noradrenergic transmission
• Effective for hyperactivity/impulsivity; less effect on inattention
• Good for comorbid tic disorders or aggression
• Side effects: sedation, bradycardia, hypotension
• Often added to stimulants for incomplete response

---

Side Effects and Management

Common stimulant side effects:

• Appetite suppression — take with or after breakfast; ensure adequate nutrition; "medication holidays" on weekends/summers for growing children
• Sleep onset insomnia — use shorter-acting formulations; time last dose before 3 pm
• Rebound irritability — as medication wears off; overlap with low-dose IR in afternoon
• Headache/stomachache — usually transient; take with food; reduce dose
• Elevated heart rate/blood pressure — monitor at each visit; avoid in structural heart disease

Growth effects:

Stimulants cause modest height reduction (~1-2 cm) in children with long-term use. This appears to attenuate by adulthood. Growth should be monitored and plotted on percentile charts.

Cardiovascular considerations:

Stimulants mildly increase heart rate (3-7 bpm) and systolic blood pressure (2-5 mmHg). Routine cardiac evaluation is not required in healthy children but obtain ECG if family history of sudden cardiac death, personal history of arrhythmia, or concerning symptoms.